MUC1/HER2/neu peptide-based immunotherapeutic vaccines for breast adenocarcinomas. This is an ASCO Meeting Abstract from the 2011 ASCO Annual Meeting I. This abstract does not include a full text ...

CD20 × CD3 bispecific antibodies bind to both CD20 on malignant B cells and CD3 on T cells, bringing them into close proximity, which triggers T cell-mediated killing of the targeted B cells. CD20 × ...

(1) A chimeric antigen receptor (CAR) is a modular, synthetic receptor that endows T cells with different targeting abilities. Several emerging engineering approaches aim to improve the safety, ...

Twelve patients were treated in the study. No dose-limiting toxicities were observed in the phase I portion. Two patients, both in the highest-dose cohort, experienced objective tumor responses. A ...